High CR/CRi rates were shown for olverembatinib plus blinatumomab in relapsed/refractory Ph-positive chronic myeloid leukemia and B-ALL.
News|Videos|June 27, 2025
Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel BCL2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory CLL/SLL, Demonstrate Deep and Durable Responses
Author(s)Chan Cheah, MBBS
Chan Y. Cheah, MBBS, DMSc, shares insights on updated results from the phase 1 BGB-11417 trial that were presented at the 2025 EHA Congress in Milan, Italy. The longer follow-up data demonstrate the safety and efficacy of the sonrotoclax plus zanubrutinib combination in patients with relapsed or refractory chronic lympocytic leukemia and small lymphocytic lymphoma.
Advertisement
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5